1
|
Cheng J, Dávila Saldaña BJ, Chandrakasan S, Keller M. Pediatric lymphoproliferative disorders associated with inborn errors of immunity. Clin Immunol 2024; 266:110332. [PMID: 39069111 DOI: 10.1016/j.clim.2024.110332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Revised: 07/18/2024] [Accepted: 07/24/2024] [Indexed: 07/30/2024]
Abstract
Both non-malignant and malignant lymphoproliferative disorders (LPD) are commonly seen in patients with inborn errors of immunity (IEI), which may be the presenting manifestations or may develop during the IEI disease course. Here we review the clinical, histopathological, and molecular features of benign and malignant LPD associated with IEI and recognize the diagnostic challenges.
Collapse
Affiliation(s)
- Jinjun Cheng
- Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, United States of America; Centers for Cancer & Blood Disorders and Cancer & Immunology Research, Children's National Hospital, Washington, DC, United States of America; The George Washington University School of Medicine and Health Sciences, Washington, DC, United States of America.
| | - Blachy J Dávila Saldaña
- Centers for Cancer & Blood Disorders and Cancer & Immunology Research, Children's National Hospital, Washington, DC, United States of America; The George Washington University School of Medicine and Health Sciences, Washington, DC, United States of America
| | - Shanmuganathan Chandrakasan
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States of America
| | - Michael Keller
- Centers for Cancer & Blood Disorders and Cancer & Immunology Research, Children's National Hospital, Washington, DC, United States of America; The George Washington University School of Medicine and Health Sciences, Washington, DC, United States of America
| |
Collapse
|
2
|
Garcia-Vilanova A, Allué-Guardia A, Chacon NM, Akhter A, Singh DK, Kaushal D, Restrepo BI, Schlesinger LS, Turner J, Weintraub ST, Torrelles JB. Proteomic analysis of lung responses to SARS-CoV-2 infection in aged non-human primates: clinical and research relevance. GeroScience 2024:10.1007/s11357-024-01264-3. [PMID: 38969861 DOI: 10.1007/s11357-024-01264-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Accepted: 06/21/2024] [Indexed: 07/07/2024] Open
Abstract
With devastating health and socioeconomic impact worldwide, much work is left to understand the Coronavirus Disease 2019 (COVID-19), with emphasis in the severely affected elderly population. Here, we present a proteomics study of lung tissue obtained from aged vs. young rhesus macaques (Macaca mulatta) and olive baboons (Papio Anubis) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Using age as a variable, we identified common proteomic profiles in the lungs of aged infected non-human primates (NHPs), including key regulators of immune function, as well as cell and tissue remodeling, and discuss the potential clinical relevance of such parameters. Further, we identified key differences in proteomic profiles between both NHP species, and compared those to what is known about SARS-CoV-2 in humans. Finally, we explored the translatability of these animal models in the context of aging and the human presentation of the COVID-19.
Collapse
Affiliation(s)
- Andreu Garcia-Vilanova
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA.
| | - Anna Allué-Guardia
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA.
- International Center for the Advancement of Research & Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA.
| | - Nadine M Chacon
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA
- Integrated Biomedical Sciences Program, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Anwari Akhter
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Dhiraj Kumar Singh
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Deepak Kaushal
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Blanca I Restrepo
- International Center for the Advancement of Research & Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA
- University of Texas Health Science Center at Houston, School of Public Health, Brownsville Campus, Brownsville, TX, USA
- South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Edinburg, TX, USA
| | - Larry S Schlesinger
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA
- International Center for the Advancement of Research & Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Joanne Turner
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA
- International Center for the Advancement of Research & Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA
- Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
| | - Susan T Weintraub
- Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Jordi B Torrelles
- Population Health, Host Pathogen Interactions, and Disease Prevention and Intervention Programs, Texas Biomedical Research Institute, San Antonio, TX, USA.
- International Center for the Advancement of Research & Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA.
| |
Collapse
|
3
|
TLR7 and IgM: Dangerous Partners in Autoimmunity. Antibodies (Basel) 2023; 12:antib12010004. [PMID: 36648888 PMCID: PMC9844493 DOI: 10.3390/antib12010004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Revised: 10/27/2022] [Accepted: 01/03/2023] [Indexed: 01/11/2023] Open
Abstract
The B cell antigen receptor (BCR)-repertoire is capable of recognizing a nearly unlimited number of antigens. Inevitably, the random nature of antibody gene segment rearrangement, needed in order to provide mature B cells, will generate autoreactive specificities. Once tolerance mechanisms fail to block the activation and differentiation of autoreactive B cells, harmful autoantibodies may get secreted establishing autoimmune diseases. Besides the hallmark of autoimmunity, namely IgG autoantibodies, IgM autoantibodies are also found in many autoimmune diseases. In addition to pathogenic functions of secreted IgM the IgM-BCR expressing B cell might be the initial check-point where, in conjunction with innate receptor signals, B cell mediated autoimmunity starts it fateful course. Recently, pentameric IgM autoantibodies have been shown to contribute significantly to the pathogenesis of various autoimmune diseases, such as rheumatoid arthritis (RA), autoimmune hemolytic anemia (AIHA), pemphigus or autoimmune neuropathy. Further, recent studies suggest differences in the recognition of autoantigen by IgG and IgM autoantibodies, or propose a central role of anti-ACE2-IgM autoantibodies in severe COVID-19. However, exact mechanisms still remain to be uncovered in detail. This article focuses on summarizing recent findings regarding the importance of autoreactive IgM in establishing autoimmune diseases.
Collapse
|
4
|
Nesari T, Kadam S, Vyas M, Huddar VG, Prajapati PK, Rajagopala M, More A, Rajagopala SK, Bhatted SK, Yadav RK, Mahanta V, Mandal SK, Mahto RR, Kajaria D, Sherkhane R, Bavalatti N, Kundal P, Dharmarajan P, Bhojani M, Bhide B, Harti SK, Mahapatra AK, Tagade U, Ruknuddin G, Venkatramana Sharma AP, Rai S, Ghildiyal S, Yadav PR, Sandrepogu J, Deogade M, Pathak P, Kapoor A, Kumar A, Saini H, Tripathi R. AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial. Front Public Health 2022; 10:920126. [PMID: 36052011 PMCID: PMC9424736 DOI: 10.3389/fpubh.2022.920126] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 07/18/2022] [Indexed: 01/22/2023] Open
Abstract
Objective The world continues to face the COVID-19 crisis, and efforts are underway to integrate traditional medicine interventions for its effective management. The study aimed to determine the efficacy of the "AYURAKSHA" kit in terms of post-interventional percentage of COVID-19 IgG positivity, immunity levels, and quality of life (QoL) against COVID-19. Method This was a non-randomized controlled, prospective intervention trial, done after the distribution of 80,000 AYURAKSHA kits (constituent of Sanshamani Vati, AYUSH Kadha, and Anu Taila) among Delhi police participants in India. Among 47,827 participants, the trial group (n = 101) was evaluated with the positivity percentage of IgG COVID-19 and Immune Status Questionnaire (ISQ) scores as a primary outcome and the WHO Quality of Life Brief Version (QOL BREF) scores along with hematological parameters as a secondary outcome in comparison to the control group (n = 71). Results The data showed that the percentage of COVID-19 IgG positivity was significantly lower in the trial group (17.5 %) as compared to the control group (39.4 %, p = 0.003), indicating the lower risk (55.6%) of COVID-19 infection in the trial group. The decreased incidence (5.05%) and reduced mortality percentage (0.44%) of COVID-19 among Delhi police officers during peak times of the pandemic also corroborate our findings. The ISQ score and WHO-QOL BREF tool analysis showed the improved scores in the trial group when compared with the controls. Furthermore, no dysregulated blood profile and no increase in inflammation markers like C-reactive protein, erythrocyte sedimentation rate, Interleukin-6 (IL-6) were observed in the trial group. However, significantly enhanced (p = 0.027) IL-6 levels and random blood sugar levels were found in the control group (p = 0.032), compared to a trial group (p = 0.165) post-intervention. Importantly, the control group showed more significant (p = 0.0001) decline in lymphocyte subsets CD3+ (% change = 21.04), CD4+ (% change = 20.34) and CD8+ (% change = 21.54) levels than in trial group, confirming more severity of COVID-19 infection in the control group. Conclusion The AYURAKSHA kit is associated with reduced COVID-19 positivity and with a better quality of life among the trial group. Hence, the study encourages in-depth research and future integration of traditional medicines for the prevention of the COVID-19 pandemic. Clinical trial registration http://ctri.nic.in/, identifier: CTRI/2020/05/025171.
Collapse
Affiliation(s)
- Tanuja Nesari
- All India Institute of Ayurveda (AIIA), New Delhi, India,*Correspondence: Tanuja Nesari
| | - Sujata Kadam
- Department of Prasuti and Stri Roga (Obstetrics and Gynaecology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Mahesh Vyas
- Department of Maulik Siddhant (Fundamental Principles), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Vitthal G. Huddar
- Department of Kaya Chikitsa (Internal Medicine), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Pradeep Kumar Prajapati
- Department of Ras Shastra and Bhaishajya Kalpana (Ayurvedic Pharmaceutics), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Manjusha Rajagopala
- Department of Shalakya Tantra (Eye and ENT), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Anand More
- Department of Roga Nidan and Vikriti Vigyan (Pathology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Shri krishna Rajagopala
- Department of Bala Roga (Pediatrics), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Santosh Kumar Bhatted
- Department of Panchkarma (Penta Bio-Purification Methods), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Rama Kant Yadav
- Department of Kaya Chikitsa (Internal Medicine), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Vyasdeva Mahanta
- Department of Shalya Tantra (Surgery), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Sisir Kumar Mandal
- Department of Roga Nidan and Vikriti Vigyan (Pathology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Raja Ram Mahto
- Department of Kaya Chikitsa (Internal Medicine), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Divya Kajaria
- Department of Kaya Chikitsa (Internal Medicine), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Rahul Sherkhane
- Department of Shalya Tantra (Surgery), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Narayan Bavalatti
- Department of Shalakya Tantra (Eye and ENT), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Pankaj Kundal
- Department of Shalakya Tantra (Eye and ENT), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Prasanth Dharmarajan
- Department of Panchkarma (Penta Bio-Purification Methods), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Meera Bhojani
- Department of Shareer Kriya (Physiology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Bhargav Bhide
- Department of Dravya Guna (Materia Medica and Pharmacology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Shiva Kumar Harti
- Department of Swastha Vritta (Preventive and Social Medicine), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Arun Kumar Mahapatra
- Department of Bala Roga (Pediatrics), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Umesh Tagade
- All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Galib Ruknuddin
- Department of Ras Shastra and Bhaishajya Kalpana (Ayurvedic Pharmaceutics), All India Institute of Ayurveda (AIIA), New Delhi, India
| | | | - Shalini Rai
- Department of Roga Nidan and Vikriti Vigyan (Pathology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Shivani Ghildiyal
- Department of Dravya Guna (Materia Medica and Pharmacology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Pramod R. Yadav
- Department of Ras Shastra and Bhaishajya Kalpana (Ayurvedic Pharmaceutics), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Jonah Sandrepogu
- Department of Kaya Chikitsa (Internal Medicine), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Meena Deogade
- Department of Dravya Guna (Materia Medica and Pharmacology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Pankaj Pathak
- Department of Maulik Siddhant (Fundamental Principles), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Alka Kapoor
- Hospital - All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Anil Kumar
- All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Heena Saini
- Department of Roga Nidan and Vikriti Vigyan (Pathology), All India Institute of Ayurveda (AIIA), New Delhi, India
| | - Richa Tripathi
- Department of Roga Nidan and Vikriti Vigyan (Pathology), All India Institute of Ayurveda (AIIA), New Delhi, India
| |
Collapse
|
5
|
Hyper IgM in tricho-hepato-enteric syndrome due to TTC37 mutation. Immunol Res 2022; 70:775-780. [PMID: 35776314 DOI: 10.1007/s12026-022-09305-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 06/27/2022] [Indexed: 11/05/2022]
Abstract
Tricho-hepato-enteric syndrome (THES) (OMIM #222,470) is a rare autosomal recessive syndromic enteropathy whose primary manifestations are dysmorphism, intractable diarrhea, failure to thrive, hair abnormalities, liver disease, and immunodeficiency with low serum IgG concentrations. THES is caused by mutations of either Tetratricopeptide Repeat Domain 37 (TTC37) or Ski2 like RNA Helicase (SKIV2L), genes that encode two components of the human SKI complex. Here, we report a patient with a TTC37 homozygous mutation phenotypically typical for tricho-hepato-enteric syndrome in whom extremely elevated IgM with low IgG was present at the time of diagnosis. These manifestations were not previously described in THES patients and this raised our index of suspicion towards "atypical" hyper IgM syndrome. Although the pathogenesis of immunoglobulin production dysfunction in THES is still elusive, this disorder should be considered in the differential diagnosis in patients with elevated IgM and syndromic features.
Collapse
|
6
|
Staels F, Betrains A, Willemsen M, Corvelyn A, Tousseyn T, Dierickx D, Humblet-Baron S, Liston A, Vanderschueren S, Schrijvers R. Inflammatory aortitis in a patient with type 2 hyper IgM syndrome. Rheumatology (Oxford) 2021; 60:e87-e89. [PMID: 32940674 DOI: 10.1093/rheumatology/keaa573] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- Frederik Staels
- Allergy and Clinical Immunology Research Group, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,Immunogenetics Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,VIB-KU Leuven Center for Brain and Disease Research, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium
| | - Albrecht Betrains
- Laboratory of Clinical Infectious and Inflammatory Disease, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium
| | - Mathijs Willemsen
- Immunogenetics Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,VIB-KU Leuven Center for Brain and Disease Research, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium
| | - Anniek Corvelyn
- Department of Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Thomas Tousseyn
- Translational Cell and Tissue Research, Department of Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Daan Dierickx
- Department of Hematology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Stephanie Humblet-Baron
- Immunogenetics Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,VIB-KU Leuven Center for Brain and Disease Research, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium
| | - Adrian Liston
- Immunogenetics Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,VIB-KU Leuven Center for Brain and Disease Research, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.,Laboratory of Lymphocyte Signaling and Development, Babraham Institute, Cambridge, UK
| | - Steven Vanderschueren
- Laboratory of Clinical Infectious and Inflammatory Disease, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium
| | - Rik Schrijvers
- Allergy and Clinical Immunology Research Group, Immunology and Transplantation, KU Leuven, Leuven, Belgium.,Immunogenetics Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium
| |
Collapse
|